Used as a key intermediate in the synthesis of pharmaceutical compounds, particularly in the development of targeted protein degraders such as PROTACs (Proteolysis Targeting Chimeras). Its structure enables conjugation between an E3 ligase binder and a target protein ligand, facilitating ubiquitination and subsequent degradation of disease-causing proteins. Commonly employed in oncology and neurodegenerative disease research due to its stability and reactivity in bioconjugation reactions. Also utilized in medicinal chemistry for linker construction in bifunctional molecules.